Approximately 70% of newly diagnosed breast cancers are early-stage, estrogen receptor–positive (ER-positive) and human epidermal growth factor receptor 2–negative (HER2-negative). With optimal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback